<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01339884</url>
  </required_header>
  <id_info>
    <org_study_id>10358B</org_study_id>
    <nct_id>NCT01339884</nct_id>
  </id_info>
  <brief_title>A Study of Resveratrol as Treatment for Friedreich Ataxia</brief_title>
  <official_title>An Open Label Clinical Pilot Study of Resveratrol as Treatment for Friedreich Ataxia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Murdoch Childrens Research Institute</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Friedreich's Ataxia Research Alliance</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Murdoch Childrens Research Institute</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine the effect of two doses of resveratrol taken for a
      12 week period, on frataxin levels in individuals with Friedreich ataxia. This study will
      also measure the effect of resveratrol on markers of oxidative stress, clinical measures of
      ataxia, and cardiac parameters.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Resveratrol shows promise as an agent for the treatment of Friedreich ataxia due to its
      antioxidant properties, neuroprotective effects, and ability to increase frataxin levels in
      vitro and in vivo. This clinical pilot study aims to determine the effect of two doses of
      resveratrol (1g/day and 5g/day) taken for 12 weeks, on frataxin levels in individuals with
      Friedreich ataxia. Additional outcome measures include the effect of resveratrol on markers
      of oxidative stress, clinical measures of ataxia , and cardiac parameters (including relative
      wall thickness and left ventricular mass index).
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>April 2011</start_date>
  <completion_date type="Actual">December 2012</completion_date>
  <primary_completion_date type="Actual">August 2012</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Lymphocyte frataxin level</measure>
    <time_frame>12 weeks</time_frame>
    <description>Change in lymphocyte frataxin levels at 12 weeks compared to baseline</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Oxidative stress markers</measure>
    <time_frame>12 weeks</time_frame>
    <description>Oxidative stress, as measured by a) plasma F2-isoprostanes and b) urinary 8-hydroxyl-2-deoxyguanosine levels at 12 weeks compared to baseline</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinical rating scales of ataxia</measure>
    <time_frame>12 weeks</time_frame>
    <description>Clinical rating scales of ataxia at 12 weeks will be compared to baseline. This will include: a) Friedreich Ataxia Rating Scale (FARS) b) International Cooperative Ataxia Rating Scale (ICARS) c) Scale for the Assessment and Rating of Ataxia (SARA) d) Friedreich Ataxia Functional Composite</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Echocardiogram measures</measure>
    <time_frame>12 weeks</time_frame>
    <description>Changes in structural and functional 3D echocardiogram measures from baseline to 12 weeks will be reported</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetic studies of resveratrol</measure>
    <time_frame>First 2 hours post dose</time_frame>
    <description>Pharmacokinetic data will be collected 45, 90 and 120 minutes after the first dose of resveratrol. Plasma concentration of resveratrol and its sulfate and glucuronide metabolites will be measured in ng/mL.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">27</enrollment>
  <condition>Friedreich Ataxia</condition>
  <arm_group>
    <arm_group_label>Resveratrol, 1g daily</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>15 participants will receive resveratrol 1g daily</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Resveratrol, 5g daily</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>15 participants will receive resveratrol, 5g daily</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Resveratrol</intervention_name>
    <description>Resveratrol 1g daily (500mg twice daily) for 12 weeks Resveratrol 5 daily (2.5g twice daily) for 12 weeks</description>
    <arm_group_label>Resveratrol, 1g daily</arm_group_label>
    <arm_group_label>Resveratrol, 5g daily</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Adults with Friedreich ataxia due to homozygosity for the GAA repeat expansion in
             intron 1 of the FXN gene

          -  Functional stage on the Ataxia subscale of the FARS of 1 or higher

        Exclusion Criteria:

          -  Women who are pregnant or lactating

          -  Active arrythmias or significant cardiac insufficiency

          -  Use of idebenone, Coenzyme Q or vitamin E within 30 days prior to enrolment

          -  Use of amiodarone or other medications which may have clinically significant drug
             interactions that cannot be safely monitored
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Martin Delatycki, MBBS PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Murdoch Childrens Research Institute</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Monash Medical Centre, Southern Health</name>
      <address>
        <city>Clayton, Melbourne</city>
        <state>Victoria</state>
        <zip>3168</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Australia</country>
  </location_countries>
  <verification_date>January 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 14, 2011</study_first_submitted>
  <study_first_submitted_qc>April 20, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 21, 2011</study_first_posted>
  <last_update_submitted>January 19, 2014</last_update_submitted>
  <last_update_submitted_qc>January 19, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 22, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Murdoch Childrens Research Institute</investigator_affiliation>
    <investigator_full_name>Martin Delatycki</investigator_full_name>
    <investigator_title>Prof Martin Delatycki</investigator_title>
  </responsible_party>
  <keyword>Friedreich ataxia</keyword>
  <keyword>Resveratrol</keyword>
  <keyword>Frataxin</keyword>
  <keyword>Cardiomyopathy</keyword>
  <keyword>Oxidative stress</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ataxia</mesh_term>
    <mesh_term>Cerebellar Ataxia</mesh_term>
    <mesh_term>Friedreich Ataxia</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Resveratrol</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

